Overview
Canada biopharma's Q4 revenue grew 29% yr/yr
Net income for Q4 surged due to income tax benefit
Company repurchased 12.2 mln shares for $98.2 mln
Outlook
Aurinia expects 2026 total revenue between $315 mln and $325 mln
Company projects 2026 LUPKYNIS sales of $305 mln to $315 mln
Aurinia plans clinical studies for aritinercept in autoimmune diseases in early 2026
Result Drivers
LUPKYNIS SALES GROWTH - Net product sales of LUPKYNIS increased 29% in Q4 and 25% for the year, driving revenue growth
INCOME TAX BENEFIT - Net income surged due to a $175.1 mln income tax benefit from the release of valuation allowance on deferred tax assets
ROYALTY REVENUE DECLINE - License, collaboration, and royalty revenue decreased 38% for the year due to absence of prior year's milestone payment
Company press release: ID:nBw7fnM1ma
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Product Revenue | $74.17 mln | ||
Q4 Net Income | $210.79 mln | ||
Q4 Operating Expenses | $43.88 mln | ||
Q4 Operating Income | $33.24 mln | ||
Q4 Pretax Profit | $35.69 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $17.00, about 17.8% above its February 25 closing price of $14.43
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 18 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments